Acceleron Pharma Performance
The firm shows a Beta (market volatility) of 0.0, which signifies not very significant fluctuations relative to the market. the returns on MARKET and Acceleron Pharma are completely uncorrelated.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Acceleron Pharma has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of very healthy basic indicators, Acceleron Pharma is not utilizing all of its potentials. The recent stock price disarray, may contribute to short-term losses for the investors. ...more
| Quick Ratio | 14.32 | |
| Fifty Two Week Low | 110.72 | |
| Target High Price | 180.00 | |
| Fifty Two Week High | 189.99 | |
| Target Low Price | 113.00 |
Acceleron |
Acceleron Pharma Relative Risk vs. Return Landscape
If you would invest (100.00) in Acceleron Pharma on February 3, 2024 and sell it today you would earn a total of 100.00 from holding Acceleron Pharma or generate -100.0% return on investment over 90 days. Acceleron Pharma is currently does not generate positive expected returns and assumes 0.0% risk (volatility on return distribution) over the 90 days horizon. In different words, 0% of stocks are less volatile than Acceleron, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Acceleron Pharma Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Acceleron Pharma's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Acceleron Pharma, and traders can use it to determine the average amount a Acceleron Pharma's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| XLRN |
Based on monthly moving average Acceleron Pharma is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Acceleron Pharma by adding Acceleron Pharma to a well-diversified portfolio.
Acceleron Pharma Fundamentals Growth
Acceleron Stock prices reflect investors' perceptions of the future prospects and financial health of Acceleron Pharma, and Acceleron Pharma fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Acceleron Stock performance.
| Return On Equity | -29.16 | |||
| Return On Asset | -16.73 | |||
| Profit Margin | (158.11) % | |||
| Operating Margin | (158.79) % | |||
| Current Valuation | 6.93 B | |||
| Shares Outstanding | 60.7 M | |||
| Price To Earning | (14.74) X | |||
| Price To Book | 13.44 X | |||
| Price To Sales | 96.57 X | |||
| Revenue | 112.94 M | |||
| EBITDA | (175.46 M) | |||
| Cash And Equivalents | 687.25 M | |||
| Cash Per Share | 11.32 X | |||
| Total Debt | 22.43 M | |||
| Debt To Equity | 0.03 % | |||
| Book Value Per Share | 13.37 X | |||
| Cash Flow From Operations | (151.71 M) | |||
| Earnings Per Share | (3.05) X | |||
| Total Asset | 146.34 M | |||
| Retained Earnings | (381.51 M) | |||
| Current Asset | 110.93 M | |||
| Current Liabilities | 14.49 M |
Things to note about Acceleron Pharma performance evaluation
Checking the ongoing alerts about Acceleron Pharma for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Acceleron Pharma help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Acceleron Pharma is not yet fully synchronised with the market data | |
| Acceleron Pharma has some characteristics of a very speculative penny stock | |
| Acceleron Pharma has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 112.94 M. Net Loss for the year was (178.56 M) with loss before overhead, payroll, taxes, and interest of (81.39 M). | |
| Acceleron Pharma currently holds about 687.25 M in cash with (151.71 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 11.32. | |
| Over 91.0% of the company outstanding shares are owned by institutional investors |
- Analyzing Acceleron Pharma's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Acceleron Pharma's stock is overvalued or undervalued compared to its peers.
- Examining Acceleron Pharma's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Acceleron Pharma's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Acceleron Pharma's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Acceleron Pharma's stock. These opinions can provide insight into Acceleron Pharma's potential for growth and whether the stock is currently undervalued or overvalued.
Check out Your Current Watchlist to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Portfolio Comparator module to compare the composition, asset allocations and performance of any two portfolios in your account.
Other Consideration for investing in Acceleron Stock
If you are still planning to invest in Acceleron Pharma check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Acceleron Pharma's history and understand the potential risks before investing.
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. |